Q2 2026 revenue grew to $163.5M, with operating and net losses narrowing significantly year-over-year. Clinical pipeline advanced with multiple Phase 1 trials, and strategic partnerships expanded, notably in China and with Entera Bio.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.